GlassScriptPhysician profile
Laura Scott
NPI 1346836764
$5,448.58
in general payments reported to CMS, 2019-2025
25 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,011 · 2023: $865 · 2024: $1,421 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,014 · Education: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,014.25 |
| Education | $423.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,114.44 | 2022-2025 | |
| Janssen Biotech, INC. | $725.03 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $571.22 | 2022-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $451.11 | 2022-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $404.19 | 2022-2023 | Sotyktu |
| Incyte Corporation | $356.76 | 2022-2025 | Opzelura, Opzelura |
| Pfizer INC. | $279.62 | 2023-2024 | |
| Lilly USA, LLC | $261.90 | 2022-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $238.12 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $203.06 | 2025 | Adbry, Anzupgo |
| Atricure, INC. | $133.04 | 2023-2024 | |
| Genzyme Corporation | $126.14 | 2022-2025 | |
| Amgen INC. | $106.45 | 2022-2025 | Otezla, Otezla |
| Organon LLC | $99.86 | 2025 | Vtama |
| Botanix Sb INC | $61.19 | 2025 | Sofdra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $56.30 | 2023-2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $50.29 | 2025 | |
| Ucb, INC. | $48.53 | 2025 | Bimzelx |
| Dermavant Sciences, INC. | $43.99 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.52 | 2024-2025 | Cabtreo |
| Springworks Therapeutics, INC. | $20.68 | 2025 | Gomekli |
| Merz North America, INC. | $19.23 | 2023 | Xeomin |
| Lnhc, INC | $15.94 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $15.91 | 2025 | Ycanth |
| Biofrontera INC. | $14.06 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.